The technology represents optimization and monitoring by MRI of nano sized cancer drug release in deep tumor regions. Aiming for cure for those 20 % who die from local complications. Lead time to market 1 - 2.5 y. Approved patents. USD 0.45 mill.
Posted by Gunnar Myhr Ph. D. under
CCT has a development agreement with Rikshospitalet (The National Hospital of Norway), close ties to The Radium Hospital and The Norwegian University of Science and Technology. The Company has received a grant (NOK 3.5 mill.) from "Innovation Norway" and is approved for "Skattefunn" (20 % refund of R&D expenditures) by the Research Council of Norway.
Myhr G. Multimodal cancer treatment: Real time monitoring, optimization, and synergistic effects. Technol Cancer Res Treat 2008;5; 409-414.
Myhr G. MR guided cancer treatment system for an elevated therapeutic index – a macroscopic approach. Med Hypotheses 2008;70; 665-670.
Myhr G. Multimodal ultrasound mediated drug release model in local cancer therapy. Med Hypotheses 2007;69; 1325-1333.
Myhr G, Moan J. Synergistic effects of chemotherapy and ultrasound treatment. Cancer Letters 2006;232; 206-213.
MR guided cancer treatment system. Patent No.: GB 07116662.7
Priority date: June 15, 2007. UK/USA. Approved by UK patent authorities.
Therapeutic Ultrasound System. Patent No.: WO 2006/129099
Priority date: June 2, 2005 (UK). Approved IPER by the PCT.
Therapeutic probe, method and system. US Patent No.: 7,220,258
Granted: USA, February 2007.
Apparatus for selective cell destruction within a living organism. Patent No.: PCT/NO2001/000349. Granted: Norway, April 2002, EPO (DE, ES, FR, UK, IT), July 2005. Pending USA.